PBYI — PUMA BIOTECHNOLOGY, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1401667 ·
Last close
$7.27
Market Cap
$370.04M
52W High
$7.90
52W Low
$5.50
ADV30
271,157
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 44,814,000 | 34,390,000 | -3,828,000 | -3,753,000 | 192,699,000 | 36,193,000 | 64,283,000 |
| Dec 2025 | 75,453,000 | 52,326,000 | 17,106,000 | 13,438,000 | 216,302,000 | 29,635,000 | 85,962,000 |
| Sep 2025 | 54,475,000 | 42,302,000 | 9,573,000 | 8,844,000 | 202,862,000 | 53,525,000 | 87,594,000 |
| Jun 2025 | 52,436,000 | 40,135,000 | 6,636,000 | 5,855,000 | 194,916,000 | 54,662,000 | 90,198,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$41,802,000
Investing CF
$-36,188,000
Financing CF
$-45,198,000
CapEx
$-123,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.61
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,283,775,000
Inventory
$5,515,000
Receivables
$53,654,000
ST Investments
$67,893,000
EBIT TTM
$42,404,000
Pretax Income TTM
$35,782,000
Interest Exp TTM
$6,622,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$227,178,000
EBITDA
$39,413,000
Free Cash Flow
$44,085,376
Enterprise Value
$284,448,032
Total Cash
$101,545,000
Total Debt
$15,954,000
Shares Out
50,899,456
Trailing EPS
$0.48
Book Value
$2.52
ROE
21.6%
ROA
9.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 228,371,000 | 37,299,000 | 31,111,000 | 216,302,000 | 85,962,000 | — | 41,802,000 |
| Dec 2024 | 230,468,000 | 30,966,000 | 30,278,000 | 213,333,000 | 121,208,000 | — | 38,918,000 |
| Dec 2023 | 235,637,000 | 32,640,000 | 21,591,000 | 230,528,000 | 177,086,000 | — | 27,009,000 |
| Dec 2022 | 228,031,000 | 30,720,000 | 2,000 | 222,059,000 | 200,451,000 | — | -15,827,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $373.39M | $0.35 | — |
| VNDA | Vanda Pharmaceuticals Inc. | $374.04M | $6.22 | — |
| AVIR | Atea Pharmaceuticals, Inc. | $362.52M | $4.53 | — |
| GLSI | Greenwich LifeSciences, Inc. | $379.48M | $27.39 | — |
| LRMR | Larimar Therapeutics, Inc. | $360.47M | $3.47 | — |
News headlines (Yahoo Finance, 1h cache)
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
2026-05-14 12:04 · Yahoo
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
2026-05-11 13:04 · Yahoo
Puma (PBYI) Q1 2026 Earnings Call Transcript
2026-05-08 20:14 · Yahoo
Puma Biotechnology Q1 Earnings Call Highlights
2026-05-08 19:12 · Yahoo
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
2026-05-08 16:03 · Yahoo
Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary
2026-05-08 12:30 · Yahoo
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
2026-05-07 23:05 · Yahoo
Puma Biotechnology Reports First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-05-06 21:15 · Yahoo
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
2026-04-23 20:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.